Andrew B Lassman
Columbia University · NRG Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew B Lassman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04421378 · A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaKaryopharm Therapeutics Inc · terminated · Glioblastoma Multiforme · principal investigator
- Ph2/Ph3NCT04396860 · Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaNational Cancer Institute (NCI) · completed · Gliosarcoma, MGMT-Unmethylated Glioblastoma · principal investigator
- Ph1NCT02238496 · Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasAndrew B Lassman, MD · completed · Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA013696 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2020 to 2026 · $448,660 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Trials Specialist in NCI Clinical Trials ResearchR50CA288588 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2025 to 2026 · $193,926 awarded in 2026Same name and institution; not confirmed by an ID
- Columbia University Minority/Underserved Site NCI Community Oncology Research ProgramUG1CA189960 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2014 to 2021 · $1,021,013 awarded in 2021Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT04396860
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:58 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Neuro Oncol · 2015230 citationsRCR 8.3
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.Neuro Oncol · 2010220 citationsRCR 5.3
- Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.Clin Cancer Res · 2005206 citationsRCR 3.9
- Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.J Clin Oncol · 2011175 citationsRCR 4.5
- 149 citationsRCR 4.0
- Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro Oncol · 2023143 citationsRCR 13.8
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).J Neurooncol · 2009142 citationsRCR 3.2
- Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).Neuro Oncol · 2015133 citationsRCR 4.1
- Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.J Clin Oncol · 2009132 citationsRCR 3.5
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.J Neurooncol · 2012114 citationsRCR 3.2